Clarithromycin: A Promising Immunomodulator in Sepsis

  • E. J. Giamarellos-Bourboulis
Conference paper


Severe sepsis and septic shock are among the leading causes of death, representing the 10th most common cause of death in the United States of America [1]. The high mortality rates, ranging between 35 and 50 % despite adequate antimicrobial treatment [2], have encouraged intense research efforts to better understand the mechanisms underlying the pathogenesis of sepsis. As a consequence, sepsis syndrome is now recognized as a complex entity created by an intense inflammatory reaction that is generated in the host after stimulation of the innate and adaptive immune systems by bacterial components [3].


Cystic Fibrosis Septic Shock Severe Sepsis Antimicrob Agent Pneumococcal Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heron M (2007) Deaths: leading causes for 2004. Natl Vital Stat Rep 56: 1–95PubMedGoogle Scholar
  2. 2.
    Engel C, Brunkhorst FM, Bone HG, et al (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33: 606–618CrossRefPubMedGoogle Scholar
  3. 3.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138–150CrossRefPubMedGoogle Scholar
  4. 4.
    Dellinger RP, Levy MM, Carlet JM, et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296–327CrossRefPubMedGoogle Scholar
  5. 5.
    Giamarellos-Bourboulis EJ (2008) Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 31: 12–20CrossRefPubMedGoogle Scholar
  6. 6.
    Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57: 212–216CrossRefPubMedGoogle Scholar
  7. 7.
    Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 360: 978–984CrossRefPubMedGoogle Scholar
  8. 8.
    Saiman L, Marshall BC, Mayer-Hamblett N, et al (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa._A randomized controlled trial. JAMA 290: 1749–1756CrossRefPubMedGoogle Scholar
  9. 9.
    Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP (2006) Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61: 895–902CrossRefPubMedGoogle Scholar
  10. 10.
    Martínez JA, Horcajada JP, Almela M, et al (2003) Addition of a macrolide to a beta-lactambased empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36: 389–395CrossRefPubMedGoogle Scholar
  11. 11.
    García Vázquez E, Mensa J, Martínez JA, et al (2005) Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 24: 190–195CrossRefPubMedGoogle Scholar
  12. 12.
    Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP (2007) Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 51: 3977–3982CrossRefPubMedGoogle Scholar
  13. 13.
    Metersky ML, Ma A, Houck PM, Bratzler DW (2007) Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 131: 466–473CrossRefPubMedGoogle Scholar
  14. 14.
    Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A (2009) Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J (in press)Google Scholar
  15. 15.
    Aspa J, Rajas O, Rodriguez de Castro F, et al (2006) Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27: 1010–1019PubMedGoogle Scholar
  16. 16.
    Kikuchi T, Hagiwara K, Honda Y, et al (2002) Clarithromycin suppresses lipopolysaccharideinduced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49: 745–755CrossRefPubMedGoogle Scholar
  17. 17.
    Darkes MJ, Perry CM (2003) Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2: 175–201.PubMedGoogle Scholar
  18. 18.
    Danesi R, Lupetti A, Barbara C (2003) Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 51: 939–945CrossRefPubMedGoogle Scholar
  19. 19.
    Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, et al (2004) Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrugresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48: 93–99CrossRefPubMedGoogle Scholar
  20. 20.
    Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, et al (2006) Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 6: 31CrossRefPubMedGoogle Scholar
  21. 21.
    Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, et al (2005) Clarithromycin coadministered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 25: 168–172CrossRefPubMedGoogle Scholar
  22. 22.
    Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, et al (2005) Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 37: 48–54CrossRefPubMedGoogle Scholar
  23. 23.
    Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, et al (2006) Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumonia. J Antimicrob Chemother 57: 937–944.CrossRefPubMedGoogle Scholar
  24. 24.
    Baziaka F, Giamarellos-Bourboulis EJ, Raftogiannis M, et al (2008) Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa. J Chemother 20: 63–68PubMedGoogle Scholar
  25. 25.
    Vincent JL, Sun Q, Dubois MJ (2003) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34: 1084–1093CrossRefGoogle Scholar
  26. 26.
    Giamarellos-Bourboulis EJ (2008) Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents (in press)Google Scholar
  27. 27.
    Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46: 1157–1164CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • E. J. Giamarellos-Bourboulis
    • 1
  1. 1.4th Department of Internal MedicineAttikon University HospitalAthensGreece

Personalised recommendations